Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.

Creative Commons License

Miles D., Gligorov J., André F., Cameron D., Schneeweiss A., Barrios C., ...Daha Fazla

Annals of oncology : official journal of the European Society for Medical Oncology, cilt.32, ss.994-1004, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 32
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1016/j.annonc.2021.05.801
  • Dergi Adı: Annals of oncology : official journal of the European Society for Medical Oncology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, CAB Abstracts, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.994-1004
  • Anahtar Kelimeler: advanced breast cancer, atezolizumab, immune checkpoint inhibitor, PD-L1, paclitaxel, triple-negative breast cancer
  • Bursa Uludağ Üniversitesi Adresli: Evet

Özet

Background: In the phase III IMpassion130 trial, combining atezolizumab with first-line nanoparticle albumin-bound-paclitaxel for advanced triple-negative breast cancer (aTNBC) showed a statistically significant progression-free survival (PFS) benefit in the intention-to-treat (ITT) and programmed death-ligand 1 (PD-L1)-positive populations, and a clinically meaningful overall survival (OS) effect in PD-L1-positive aTNBC. The phase III KEYNOTE-355 trial adding pembrolizumab to chemotherapy for aTNBC showed similar PFS effects. IMpassion131 evaluated first-line atezolizumab-paclitaxel in aTNBC.